Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $405000.0.

  • Theravance Biopharma's Depreciation & Amortization (CF) fell 559.44% to $405000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 184.52%. This contributed to the annual value of $1.7 million for FY2024, which is 1454.27% down from last year.
  • Per Theravance Biopharma's latest filing, its Depreciation & Amortization (CF) stood at $405000.0 for Q3 2025, which was down 559.44% from $409000.0 recorded in Q2 2025.
  • Theravance Biopharma's Depreciation & Amortization (CF)'s 5-year high stood at $1.6 million during Q3 2021, with a 5-year trough of $251000.0 in Q4 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $432000.0 (2023), whereas its average is $708210.5.
  • Per our database at Business Quant, Theravance Biopharma's Depreciation & Amortization (CF) skyrocketed by 16254.98% in 2022 and then tumbled by 6101.08% in 2023.
  • Over the past 5 years, Theravance Biopharma's Depreciation & Amortization (CF) (Quarter) stood at $251000.0 in 2021, then skyrocketed by 162.55% to $659000.0 in 2022, then plummeted by 40.52% to $392000.0 in 2023, then grew by 7.65% to $422000.0 in 2024, then fell by 4.03% to $405000.0 in 2025.
  • Its last three reported values are $405000.0 in Q3 2025, $409000.0 for Q2 2025, and $413000.0 during Q1 2025.